Literature DB >> 19680779

Effect of iron overload on exercise capacity in thalassemic patients with heart failure.

Sophie Mavrogeni1, Efstathios Gotsis, Dimitrios Verganelakis, Eleni Berdousis, Athanasios Dritsas, Genovefa Kolovou, Panagiotis Toulas, Vassilios Ladis.   

Abstract

In b-thalassemia, myocardial iron overload contributes to heart failure, despite chelation treatment. We hypothesized that myocardial T2*, an index of iron overload, influences patients' physical activity. We assessed a thalassemic population by both cardiovascular magnetic resonance imaging (CMR) and ergospirometry test. Sixty-six thalassemic patients aged 27 (19-40) years, 30 without (NHF) and 36 with heart failure (HF), were studied. Cardiac T2* and left ventricular ejection fraction (LVEF) were evaluated using a 1.5 T system. VO(2max), AT, Mets and duration of exercise by ergospirometry were also assessed. Myocardial T2* was lower in HF compared to NHF patients (14.7 +/- 6.6 vs. 39 +/- 2 ms, P < 0.001). LVEDV and LVESV were higher in HF group compared to NHF patients (139.9 +/- 16.3 vs. 124.6 +/- 20.86 ml, P < 0.01 and 94.9 +/- 24 vs. 38.3 +/- 10.1 ml, P < 0.001, respectively). Additionally, LVEF in HF was lower compared to NHF patients (21.3 +/- 6.1% vs. 69.6 +/- 3.7, P < 0.001, respectively). All exercise parameters were lower in HF compared to NHF patients (P < 0.001). Patients within the HF group were additionally analyzed according to T2* values (<10 ms). HF patients with T2* < 10 ms (n = 13) were considered as high iron overloaded (HF-H) and the rest of them (n = 23) as (HF-L). Although LVEDV, LVESV, LVEF were similar in the two subgroups, the exercise parameters were significantly lower in the HF-H group (P < 0.001). Heart T2* correlated with all exercise parameters (P < 0.001). HF thalassemic patients have reduced exercise indexes compared to non HF. Myocardial iron overload, expressed as T2*, has a direct influence on exercise capacity, independent of LV ejection fraction and functional class.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19680779     DOI: 10.1007/s10554-009-9491-9

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  27 in total

1.  Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool.

Authors:  Peter D Jensen; Finn T Jensen; Thorkil Christensen; Hans Eiskjaer; Ulrik Baandrup; Johan L Nielsen
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

2.  The use of an exponential protocol for bicycle and treadmill exercise testing in patients with chronic cardiac failure.

Authors:  M Riley; D B Northridge; E Henderson; C F Stanford; D P Nicholls; H J Dargie
Journal:  Eur Heart J       Date:  1992-10       Impact factor: 29.983

3.  Echocardiographic and electrocardiographic prognostic factors of heart failure in young patients with beta-thalassemia major: a 10-year (1995--2004) follow-up.

Authors:  Christina Chrysohoou; Demosthenes B Panagiotakos; Yannis Barbetseas; Stella Brilli; Spyros Lambrou; Markissia Karagiorga; Vassilis A Ladis; Christos Pitsavos; Christodoulos Stefanadis
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

4.  Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure.

Authors:  M Metra; P Faggiano; A D'Aloia; S Nodari; A Gualeni; D Raccagni; L Dei Cas
Journal:  J Am Coll Cardiol       Date:  1999-03-15       Impact factor: 24.094

Review 5.  T2* magnetic resonance and myocardial iron in thalassemia.

Authors:  Dudley J Pennell
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

6.  Bimodal cardiac dysfunction in an animal model of iron overload.

Authors:  Tianen Yang; Wei-Qiang Dong; Yuri A Kuryshev; Carlos Obejero-Paz; Matthew N Levy; Gary M Brittenham; Songsak Kiatchoosakun; Darryl Kirkpatrick; Brian D Hoit; Arthur M Brown
Journal:  J Lab Clin Med       Date:  2002-10

7.  Myocardial and hepatic T2* magnetic resonance evaluation in ex-thalassemic patients after bone-marrow transplantation.

Authors:  Sophie Mavrogeni; Efstathios D Gotsis; Eleni Berdousi; Vasilios Ladis; Dimitrios Verganelakis; Panagiotis Toulas; Dennis V Cokkinos
Journal:  Int J Cardiovasc Imaging       Date:  2007-01-19       Impact factor: 2.357

8.  Detection of early cardiac dysfunction in patients with severe beta-thalassemia and chronic iron overload.

Authors:  M B Leon; J S Borer; S L Bacharach; M V Green; E J Benz; P Griffith; A W Nienhuis
Journal:  N Engl J Med       Date:  1979-11-22       Impact factor: 91.245

9.  Quantification of cardiac and tissue iron by nuclear magnetic resonance relaxometry in a novel murine thalassemia-cardiac iron overload model.

Authors:  P Liu; M Henkelman; J Joshi; P Hardy; J Butany; M Iwanochko; M Clauberg; M Dhar; D Mai; S Waien; N Olivieri
Journal:  Can J Cardiol       Date:  1996-02       Impact factor: 5.223

10.  Cardiac pathology in 76 thalassemic patients.

Authors:  D Sonakul; K Thakerngpol; P Pacharee
Journal:  Birth Defects Orig Artic Ser       Date:  1988
View more
  5 in total

Review 1.  Transition metals and mitochondrial metabolism in the heart.

Authors:  Amy K Rines; Hossein Ardehali
Journal:  J Mol Cell Cardiol       Date:  2012-06-02       Impact factor: 5.000

2.  Cardiopulmonary exercise testing in thalassemia.

Authors:  John-Paul Carpenter; Dudley J Pennell
Journal:  Int J Cardiovasc Imaging       Date:  2009-11-24       Impact factor: 2.357

Review 3.  Iron overload cardiomyopathy: better understanding of an increasing disorder.

Authors:  Pradeep Gujja; Douglas R Rosing; Dorothy J Tripodi; Yukitaka Shizukuda
Journal:  J Am Coll Cardiol       Date:  2010-09-21       Impact factor: 24.094

4.  Dynamic dyssynchrony and impaired contractile reserve of the left ventricle in beta-thalassaemia major: an exercise echocardiographic study.

Authors:  Yiu-fai Cheung; Wei Yu; Shu-na Li; Wendy W M Lam; Yuen-chi Ho; Sophia J Wong; Godfrey C F Chan; Shau-yin Ha
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

5.  Management of cardiac hemochromatosis.

Authors:  Wilbert S Aronow
Journal:  Arch Med Sci       Date:  2017-06-30       Impact factor: 3.318

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.